Expanding the Generic Pharmaceutical Business Primarily through In-House Sales

「Although authorized generic sales fell below the previous fiscal year, sales of generic drugs rose 3.7% from the previous fiscal year to ¥38,451 million, helped by sales contributions from products launched in 2024 and the impact of selective medical care for long-listed products, among other factors.」

「Although authorized generic sales fell below the year-earlier level, sales of generic drugs rose 7.2% year on year to ¥16,822 million, helped by sales contributions from products launched in 2024 and the impact of selective medical care for long-listed products, among other factors.」

「The company focused its efforts on addressing stable-supply issues and expanding sales of major products. Generic drug sales rose 1.4% from the previous fiscal year to ¥37,068 million.」

「The company focused its efforts on addressing stable-supply issues and expanding sales, but sales of authorized generics fell below the previous interim consolidated accounting period, resulting in generic drug sales of ¥15,686 million, down 7.2% year on year.」

「The company focused its efforts on addressing stable-supply issues and expanding sales of newly supplementary-listed products. As a result, sales exceeded the year-earlier level and rose 4.7% year on year to ¥16,895 million.」

「The company focused its efforts on addressing stable-supply issues, while sales benefited from newly supplementary-listed products and exceeded the year-earlier level. Sales therefore rose 9.3% year on year to ¥8,854 million.」

「The company focused its efforts on addressing concerns over stable supply arising from quality issues at certain generic drug companies, while working to expand sales of newly supplementary-listed products and priority products. As a result, sales rose to ¥26,119 million, up 5.1% year on year, driven by sales of products including the authorized generic of Kipres, which exceeded the year-earlier level.」

「The company focused its efforts on addressing concerns about supply stability stemming from quality problems at certain generic drug companies and worked to expand sales of newly listed products and重点 products. As a result, the performance of the authorized generic of Kipres and other products exceeded the same period of the previous year, bringing sales to ¥16.128 billion, up 4.2% year on year.」

「The company focused its efforts on addressing supply-stability issues stemming from quality problems at certain generic drug companies, while the performance of the authorized generic of Kipres and other products exceeded the same period of the previous year, bringing sales to ¥8.103 billion, up 5.6% year on year.」

「The performance of 3 AG products, including the authorized generic of Kipres, exceeded the same period of the previous year, while products newly listed for sale in June and December 2021 also contributed, bringing sales to ¥24.855 billion, compared with ¥22.528 billion in the same period of the previous year.」

「The performance of 3 AG products, including the authorized generic of Kipres, exceeded the previous year, while products newly listed for sale in June 2021 also contributed, bringing sales to ¥15.481 billion, compared with ¥14.351 billion in the same period of the previous year.」

「The performance of the Kipres and Nasonex authorized generics exceeded the previous year, while products newly listed for sale in June 2021 also contributed, bringing sales to ¥7.674 billion, compared with ¥7.458 billion in the same period of the previous year.」

「Sales of the Nasonex AG increased, while the Uritos AG, launched in June 2020, and products newly launched during the current fiscal year also contributed, bringing sales to ¥22.528 billion, up 2.2% year on year.」

「Sales of the Nasonex AG, launched in August 2019, increased, while the Uritos AG, launched in June 2020, also contributed, bringing sales to ¥14.351 billion, up 1.3% year on year.」

「Sales of the Nasonex authorized generic (AG), launched in August 2019, increased, while the Uritos AG, launched in June 2020, also contributed, bringing sales to ¥7.458 billion, up 2.1% year on year.」

「Sales of mometasone, the authorized generic of Nasonex launched in August 2019, contributed, bringing sales to ¥30.957 billion, up 5.5% from the previous fiscal year.」

「Sales of mometasone, the authorized generic of Nasonex launched in August 2019, contributed, bringing sales to ¥22.038 billion, up 2.8% year on year.」

「Driven primarily by higher sales of mometasone, the authorized generic of Nasonex, sales were ¥14.166 billion, up 4.5% year on year.」

「Driven primarily by lower sales of the authorized generic of montelukast, the authorized generic of Kipres, sales were ¥7.304 billion, down 3.0% year on year.」

「Sales of Montelukast Tablets “KM,” the authorized generic of Kipres and Singulair, increased, while products newly listed for sale during the current fiscal year also contributed, bringing sales to ¥29.334 billion, an increase of ¥1.672 billion, or 6.0%, from the previous fiscal year.」

「Higher sales of Montelukast Tablets “KM,” the authorized generic of Kipres and Singulair, together with contributions from products newly listed for sale during the current fiscal year, brought sales to ¥21.436 billion, up 4.1% year on year.」

「Higher sales of Montelukast Tablets “KM,” the authorized generic of Kipres and Singulair, together with contributions from products newly listed for sale during the current fiscal year, brought sales to ¥13.552 billion, up 4.2% year on year.」

「Driven primarily by higher sales of the authorized generic of montelukast, the authorized generic of Kipres and Singulair, sales were ¥7.531 billion, up 9.6% year on year.」

「The company launched the authorized generic (AG) of montelukast in fiscal 2016 and captured more than 50% of the generic drug market. Going forward, it will promote the rollout of the next AG.」

「In response to the expiration of the patent for Kipres, Kyorin Pharmaceutical Co., Ltd.’s flagship treatment for bronchial asthma and allergic rhinitis, sales of Montelukast Tablets 10 mg and 5 mg “KM,” launched by Kyorin Rimedio Co., Ltd. in September 2016, increased substantially, bringing sales to ¥20.582 billion, up 13.7% year on year.」

「Driven primarily by a substantial increase in sales of Montelukast Tablets 10 mg and 5 mg “KM,” generic drug sales were ¥13.005 billion, up 26.0% year on year.」

「As a result, the substantial increase in sales of this drug was a major contributor, and total generic drug sales were ¥6.870 billion, up 49.1% year on year.」

「Total generic drug sales were ¥25.024 billion, up 62.0% year on year.」

「Sales of Montelukast Tablets 10 mg and 5 mg “KM,” a treatment for bronchial asthma and allergic rhinitis launched by Kyorin Rimedio Co., Ltd. in September 2016, increased, while sales of products other than this drug also exceeded the previous year, bringing total generic drug sales to ¥18.101 billion, up 58.5% year on year.」

「In addition, sales of products other than this drug exceeded the previous year, led by in-house sales, and total generic drug sales were ¥10.321 billion, up 39.8% year on year.」

「Sales exceeded the prior-year level, driven primarily by in-house sales.」